abrdn World Healthcare Fund Q4 2024 Commentary

2025-03-30 07:10:00 ET

Summary

• The abrdn World Healthcare Fund outperformed its custom benchmark, driven by strong performances from uniQure, Oculis Holding, and New Amsterdam Pharma Company.
• Global equity markets dipped slightly, but optimism rose due to Trump's election win and resilient economic data, despite concerns over China and geopolitical risks.
• New positions in Humana, Tempus AI, Oxford Biomedica, and Exact Sciences were established, while Illumina, Edwards Lifesciences, and Acadia Healthcare were sold.
• Focus remains on diversifying the portfolio with high-quality businesses to withstand volatility, with a favorable long-term outlook for healthcare due to demographic trends.

Fund performance

The equity portion of the Fund fell (gross of fees) but outperformed its custom benchmark over the quarter. ¹ ...

Read the full article on Seeking Alpha

For further details see: